← Evidence map

ArticleHaematologica2026

CPX-351 in secondary/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3,200 patients.

Matteo Molica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

CPX-351 in secondary/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3,200 patients. | Socratic